NCI Press Release In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1
Biochemically Silent Sympathetic Paraganglioma, Pheochromocytoma, or Metastatic Disease in SDHD Mutation Carriers Full story >
